The high prevalence of the MYC oncogene in SCLC may account for this discrepancy [44], as elevated MYC expression has been associated with reduced survival following anti-PD-L1 treatment in solid tumors [45,46,47,48]. The gene discussed is MYC; the disease is small cell lung carcinoma.